CALR MPN mutations have an entirely different mechanism of activating JAK-STAT signaling, which involves presenting MPL itself at the cell surface either activated [94] or capable of interacting with thrombopoietin. This evidence concerns the gene MPL and myeloproliferative neoplasm.